Literature DB >> 17938191

Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.

Charalampos Antachopoulos1, Joseph Meletiadis, Tin Sein, Emmanuel Roilides, Thomas J Walsh.   

Abstract

The concentration-dependent effects of echinocandins on the metabolic activity of Aspergillus spp. were comparatively studied by using nongerminated and germinated conidia. The susceptibilities of 11 Aspergillus fumigatus, 8 A. terreus and 8 A. flavus isolates to caspofungin, micafungin, and anidulafungin were studied by a CLSI (formerly NCCLS) M38-A broth microdilution-based method. After 48 h of incubation the minimum effective concentration (MEC) was defined microscopically. Metabolic activity was assessed by the 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide assay and modeled by using the sigmoid (E max) or "bell-shaped" model. The median MEC values of caspofungin (0.5 to 1 microg/ml), micafungin (0.06 to 0.12 microg/ml), and anidulafungin (0.03 microg/ml) against nongerminated conidia increased by 0 to 1, 1 to 2, and 2 to 3 twofold dilutions, respectively (depending on the species), over those against germinated conidia. A similar shift to the right was demonstrated for the corresponding curves of metabolic activity. There was a significant correlation between the degrees of maximal metabolic inhibition caused by different echinocandins at both the species level (greater inhibition for A. flavus) and the strain level (r = 0.84 to 0.93; P < 0.0001). Paradoxical increases in metabolism in the presence of higher concentrations of caspofungin, micafungin, and anidulafungin were detected in 6, 2, and 5 of the A. fumigatus isolates, respectively; 5, 1, and 2 of the A. terreus isolates, respectively; and 1, 0, and 0 of the A. flavus isolates, respectively. Based on the model, 50% of the maximal paradoxical increase was detected with 4.2, 11.1, and 10.8 microg/ml of caspofungin, micafungin, and anidulafungin, respectively. All echinocandins therefore exerted comparable levels of maximal metabolic inhibition against Aspergillus spp. at concentrations that were differentially increased for germinated versus nongerminated conidia. The paradoxical increase in metabolism occurred more frequently and at lower concentrations with caspofungin than with micafungin and anidulafungin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938191      PMCID: PMC2223904          DOI: 10.1128/AAC.00699-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

Review 1.  Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin.

Authors:  R E Gardiner; P Souteropoulos; S Park; D S Perlin
Journal:  Med Mycol       Date:  2005-05       Impact factor: 4.076

2.  Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin.

Authors:  David A Stevens; Masayuki Ichinomiya; Yukako Koshi; Hiroyuki Horiuchi
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.

Authors:  Johan Maertens; Issam Raad; George Petrikkos; Marc Boogaerts; Dominik Selleslag; Finn B Petersen; Carole A Sable; Nicholas A Kartsonis; Angela Ngai; Arlene Taylor; Thomas F Patterson; David W Denning; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2004-11-09       Impact factor: 9.079

4.  Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.

Authors:  Anthony Cacciapuoti; Judith Halpern; Cara Mendrick; Christine Norris; Reena Patel; David Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

5.  Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.

Authors:  Kathrin Heyn; Antje Tredup; Stefanie Salvenmoser; Frank-Michael C Müller
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans.

Authors:  J C Bowman; G K Abruzzo; A M Flattery; C J Gill; E J Hickey; M J Hsu; J Nielsen Kahn; P A Liberator; A S Misura; B A Pelak; T C Wang; C M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

7.  Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro.

Authors:  Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  J Antimicrob Chemother       Date:  2005-09-27       Impact factor: 5.790

8.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

Authors:  Nathan P Wiederhold; Dimitrios P Kontoyiannis; Jingduan Chi; Randall A Prince; Vincent H Tam; Russell E Lewis
Journal:  J Infect Dis       Date:  2004-09-10       Impact factor: 5.226

10.  Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Kieren A Marr; Wendi M Lau; David P Facklam; Voravit Ratanatharathorn; Cornelia Becker; Andrew J Ullmann; Nita L Seibel; Patricia M Flynn; Jo-Anne H van Burik; Donald N Buell; Thomas F Patterson
Journal:  J Infect       Date:  2006-05-06       Impact factor: 6.072

View more
  33 in total

1.  The composition of the culture medium influences the β-1,3-glucan metabolism of Aspergillus fumigatus and the antifungal activity of inhibitors of β-1,3-glucan synthesis.

Authors:  Cécile Clavaud; Anne Beauvais; Lise Barbin; Hélène Munier-Lehmann; Jean-Paul Latgé
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

2.  Profiling the Aspergillus fumigatus proteome in response to caspofungin.

Authors:  Steven E Cagas; Mohit Raja Jain; Hong Li; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

Review 3.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Bronchopulmonary disposition of micafungin in healthy adult volunteers.

Authors:  Anthony M Nicasio; Pamela R Tessier; David P Nicolau; R Fredrick Knauft; John Russomanno; Eric Shore; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

Review 5.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

Review 6.  Caspofungin: in pediatric patients with fungal infections.

Authors:  Karly P Garnock-Jones; Susan J Keam
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

7.  In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.

Authors:  Shawn R Lockhart; Alicia J Zimbeck; John W Baddley; Kieren A Marr; David R Andes; Thomas J Walsh; Carol A Kauffman; Dimitrios P Kontoyiannis; James I Ito; Peter G Pappas; Tom Chiller
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

8.  Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece.

Authors:  Michael Arabatzis; Manousos Kambouris; Miltiades Kyprianou; Aikaterini Chrysaki; Maria Foustoukou; Maria Kanellopoulou; Lydia Kondyli; Georgia Kouppari; Chrysa Koutsia-Karouzou; Evangelia Lebessi; Anastasia Pangalis; Efthimia Petinaki; Ageliki Stathi; Eleftheria Trikka-Graphakos; Erriketi Vartzioti; Aliki Vogiatzi; Timoleon-Achilleas Vyzantiadis; Loukia Zerva; Aristea Velegraki
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

9.  Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Authors:  Jared L Crandon; Mary Anne Banevicius; Annie F Fang; Penelope H Crownover; R Fredrick Knauft; J Samuel Pope; John H Russomanno; Eric Shore; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

10.  Fungal echinocandin resistance.

Authors:  Louise A Walker; Neil A R Gow; Carol A Munro
Journal:  Fungal Genet Biol       Date:  2009-09-19       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.